ALNYLAM PHARMACEUTICALS, INC. (ALNY): debt financing — Alnylam enters $500M revolving credit facility maturing 2030

ALNYLAM PHARMACEUTICALS, INC.

New $500M Revolving Credit Facility includes $150M letter of credit sublimit; available for working capital and general corporate purposes.
Interest rates: Term SOFR plus 1.50%–2.50% (based on Total Leverage Ratio); commitment fee 0.20%–0.35% on unused commitments.
Financial covenants: Total Net Leverage Ratio ≤ 3.75:1.00 and Consolidated Interest Coverage Ratio ≥ 3.00:1.00, tested quarterly.
Maturity September 30, 2030; springing maturity if outstanding Springing Maturity Debt exceeds $630M or 100% of EBITDA.
Guaranteed by material domestic subsidiaries and secured by substantially all assets, subject to customary exceptions and release conditions.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

ALNYLAM PHARMACEUTICALS, INC. incurred revolving credit of $500.0 million revolving line of credit with Bank of America, N.A., as Administrative Agent at term SOFR rate plus an applicable margin between 1.50% and 2.50% maturing September 30, 2030.

Instrument: revolving credit
Principal: $500.0 million revolving line of credit
Counterparty: Bank of America, N.A., as Administrative Agent
Rate: term SOFR rate plus an applicable margin between 1.50% and 2.50%
Maturity: September 30, 2030
Event: incurrence

Exact text from the filing

“Credit Agreement”) among the lenders party thereto, Bank of America, N.A., as Administrative Agent, and the other parties named therein. The Credit Agreement provides for a $500.0 million revolving line of credit (the “Revolving Credit Facility”), including a $150.0 million letter of credit sublimit. The Credit Agreement provides that the Company has the right at

View on SEC.gov

102 debt financings filed in the last 30 days. Browse all debt financings →

ALNYLAM PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-25-230201

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.